Julia Stieglmaier

2.2k total citations · 2 hit papers
24 papers, 1.4k citations indexed

About

Julia Stieglmaier is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Julia Stieglmaier has authored 24 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 8 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Immunology. Recurrent topics in Julia Stieglmaier's work include CAR-T cell therapy research (17 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Julia Stieglmaier is often cited by papers focused on CAR-T cell therapy research (17 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Julia Stieglmaier collaborates with scholars based in Germany, United States and Japan. Julia Stieglmaier's co-authors include Dirk Nagorsen, Ralf C. Bargou, Jonathan Benjamin, Nicola Gökbuget, Hervé Dombret, Gerhard Zugmaier, Monika Brüggemann, Christoph Faul, Albrecht Reichle and Hendrik Wessels and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Julia Stieglmaier

24 papers receiving 1.4k citations

Hit Papers

Blinatumomab for minimal ... 2016 2026 2019 2022 2018 2016 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
    2018 516 citations Nicola Gökbuget, Hervé Dombret et al. Blood profile →
  2. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
    2016 280 citations Andreas Viardot, Marie-Elisabeth Goebeler et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julia Stieglmaier Germany 15 938 572 413 387 364 24 1.4k
Svenja Neumann Germany 10 1.1k 1.2× 503 0.9× 268 0.6× 438 1.1× 377 1.0× 12 1.4k
Petra Klappers Germany 7 989 1.1× 418 0.7× 250 0.6× 303 0.8× 444 1.2× 8 1.4k
Hervé Dombret France 9 567 0.6× 542 0.9× 417 1.0× 243 0.6× 190 0.5× 14 1.1k
Mariele Goebeler Germany 10 1.2k 1.3× 322 0.6× 236 0.6× 299 0.8× 633 1.7× 22 1.6k
Margit Schmidt Germany 7 715 0.8× 222 0.4× 153 0.4× 211 0.5× 384 1.1× 13 1.0k
Johannes Duell Germany 18 1.3k 1.4× 150 0.3× 507 1.2× 571 1.5× 415 1.1× 72 1.7k
Prashant Tembhare India 17 300 0.3× 296 0.5× 438 1.1× 244 0.6× 180 0.5× 97 909
Dorothea Wessiepe Germany 5 497 0.5× 237 0.4× 117 0.3× 126 0.3× 198 0.5× 5 669
Steve Kornblau United States 10 369 0.4× 296 0.5× 1.2k 2.8× 87 0.2× 404 1.1× 16 1.4k
Loredana Elia Italy 18 466 0.5× 1.3k 2.2× 1.1k 2.7× 196 0.5× 86 0.2× 35 1.6k

Countries citing papers authored by Julia Stieglmaier

Since Specialization
Citations

This map shows the geographic impact of Julia Stieglmaier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Stieglmaier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Stieglmaier more than expected).

Fields of papers citing papers by Julia Stieglmaier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia Stieglmaier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Stieglmaier. The network helps show where Julia Stieglmaier may publish in the future.

Co-authorship network of co-authors of Julia Stieglmaier

This figure shows the co-authorship network connecting the top 25 collaborators of Julia Stieglmaier. A scholar is included among the top collaborators of Julia Stieglmaier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia Stieglmaier. Julia Stieglmaier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rodríguez, César A., Tulio E. Rodriguez, Alain Kentos, et al.. (2025). BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study. Leukemia & lymphoma. 66(11). 2108–2117. 1 indexed citations
2.
3.
Kelly, William Kevin, Daniel C. Danila, C-C. Lin, et al.. (2023). 264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 34. S1576–S1576. 1 indexed citations
4.
Kelly, William Kevin, Daniel C. Danila, C-C. Lin, et al.. (2023). 1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 34. S953–S954. 8 indexed citations
5.
Xu, Michael, Fabio Quaglia, Li Li, et al.. (2022). STEAP1–4 (Six-Transmembrane Epithelial Antigen of the Prostate 1–4) and Their Clinical Implications for Prostate Cancer. Cancers. 14(16). 4034–4034. 30 indexed citations
6.
Danila, Daniel C., David Waterhouse, Leonard J. Appleman, et al.. (2022). A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 40(16_suppl). TPS5101–TPS5101. 7 indexed citations
7.
Kelly, William Kevin, David Pook, Leonard J. Appleman, et al.. (2021). Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 39(6_suppl). TPS183–TPS183. 3 indexed citations
8.
Viardot, Andreas, et al.. (2020). Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Annals of Hematology. 99(10). 2215–2229. 32 indexed citations
9.
Gökbuget, Nicola, Hervé Dombret, Sebastian Giebel, et al.. (2019). Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology. 24(1). 337–348. 41 indexed citations
10.
Gökbuget, Nicola, Hervé Dombret, Massimiliano Bonifacio, et al.. (2018). Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 131(14). 1522–1531. 516 indexed citations breakdown →
11.
Viardot, Andreas, Marie-Elisabeth Goebeler, Georg Heß, et al.. (2016). Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 127(11). 1410–1416. 280 indexed citations breakdown →
12.
Gökbuget, Nicola, Hervé Dombret, Josep‐María Ribera, et al.. (2016). International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 101(12). 1524–1533. 142 indexed citations
13.
Stieglmaier, Julia, Jonathan Benjamin, & Dirk Nagorsen. (2015). Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert Opinion on Biological Therapy. 15(8). 1093–1099. 53 indexed citations
14.
15.
16.
Kellner, Christian, Joerg Bruenke, Julia Stieglmaier, et al.. (2008). A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells. Journal of Immunotherapy. 31(9). 871–884. 62 indexed citations
17.
Bremer, Edwin, Bram ten Cate, Douwe F. Samplonius, et al.. (2008). Superior Activity of Fusion Protein scFvRit:sFasL over Cotreatment with Rituximab and Fas Agonists. Cancer Research. 68(2). 597–604. 41 indexed citations
18.
Stieglmaier, Julia, Christian Kellner, Matthias Peipp, et al.. (2007). A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells. Leukemia. 21(7). 1405–1412. 23 indexed citations
19.
Stieglmaier, Julia, Edwin Bremer, Christian Kellner, et al.. (2007). Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunology Immunotherapy. 57(2). 233–246. 53 indexed citations
20.
Stieglmaier, Julia, Domenica Saul, Bernhard Stockmeyer, et al.. (2006). Influence of Variable N-Glycosylation on the Cytolytic Potential of Chimeric CD19 Antibodies. Journal of Immunotherapy. 29(2). 122–133. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Svenja Neumann Breakdown of academic impact, for papers by Petra Klappers Breakdown of academic impact, for papers by Hervé Dombret Breakdown of academic impact, for papers by Mariele Goebeler Breakdown of academic impact, for papers by Margit Schmidt Breakdown of academic impact, for papers by Johannes Duell Breakdown of academic impact, for papers by Prashant Tembhare Breakdown of academic impact, for papers by Dorothea Wessiepe Breakdown of academic impact, for papers by Steve Kornblau Breakdown of academic impact, for papers by Loredana Elia
Rankless by CCL
2026